Similar Items: Deep contrastive learning framework identifies cell‐type‐specific drug targets in Alzheimer's disease
- Alzheimer's disease drug development pipeline: 2026
- Interchangeability of CSF and PET to identify Alzheimer's disease pathology
- Polypharmacy is associated with lower progression from MCI to Alzheimer's disease, with sex‐specific patterns across drug classes
- APOE‐associated disease risk and sex‐specific effects in Egyptian Alzheimer's disease: an exploratory study
- The multifaceted roles of the transcription factor SP1 in the pathogenesis of Alzheimer's disease: From molecular regulation to therapeutic targets
- Atrophy signature for alpha‐synuclein copathology in Alzheimer's disease